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Human induced pluripotent stem cells (iPSCs) and their derivatives are needed in large numbers for various 
biomedical applications. However, scalable and cost-effective manufacturing of high quality iPSCs and their 
derivatives remains a challenge. In vivo, cells reside in a 3D microenvironment that has plenty of cell-cell and 
cell-ECM (extracellular matrix) interactions, sufficient supply of nutrients and oxygen, and minimal hydrodynamic 
stresses. The current iPSC culturing methods, however, provide highly-stressed culturing microenvironments, 
leading to low culture efficiency. For instance, we and others showed iPSCs typically expanded 4-fold/4 days to 
yield ~2.0x10^6 cells/mL with current 3D suspension culturing. These cells occupy ~0.4% of the bioreactor 
volume. To our best knowledge, the largest culture volume demonstrated to date for iPSCs is less than 10 liters.  
There is a critical need to develop new culture technologies to achieve the iPSCs’ potential. 
 
We here report a novel technology that can overcome all the limitations of current methods and provide a 
physiologically-relevant culture microenvironment. With this technology, iPSCs are processed into and cultured 
in microscale alginate hydrogel 
tubes (termed SFIT or stress-free 
intratubular cell culture) that are 
suspended in the cell culture 
medium in a culture vessel (Figs. 1A 
and B). The hydrogel tubes create 
free microspaces that allow cells to 
interact with each other and expand. 
Meanwhile, they protect cells from 
hydrodynamic stresses in the culture 
vessel and confine the cell mass 
<400 µm (in radial diameter) to ensure efficient mass transport during the entire culture (Figs. 1A and B). This 
technology is simple, scalable, defined and cGMP-compliant that make it commercially viable. We showed that, 
under optimized culture conditions, SFIT offered paradigm-shifting improvements in cell viability, growth, yield, 
culture consistency and scalability over current methods. We demonstrated long-term culturing (>10 passages) 
of iPSCs without uncontrolled differentiation and chromosomal abnormalities. Cultures between batches and cell 
lines were very consistent. iPSCs in SFIT had high viability, growth rate (1000-fold/10 days/passage in general) 
and yield (~5x10^8 cells/mL microspace). The expansion per passage (e.g. up to 4200-fold/passage was 
achieved) and volumetric yield are much higher than current methods. The high yield and high expansion fold 
significantly reduce the culture volume and time, numbers of passaging operations, and the production cost, 
making large-scale cell production technically and conically feasible.  
 
iPSCs could be efficiently differentiated into various tissues cells in SFIT. Additionally, we have shown other 
human cells, such as T cells, could also be efficiently cultured in this technology. Two SFIT-based automated 
bioreactors for producing autologous and allogenic iPSCs and their derivatives are under developing. This 
technology has high potential to address the cell manufacturing challenge. Details of the method can be found in 
very-recent publications: Biofabrication. doi: 10.1088/1758-5090/aaa6b5; Sci Rep. doi: 10.1038/s41598-018-
21927-4; ACS Appl Mater Interfaces. doi: 10.1021/acsami.8b05780; Adv Healthc Mater. doi: 
10.1002/adhm.201701297. 
 
 
